CompletedNCT06147622
Prazosin and cyproheptadine levels in alcohol research
About this title
Read the official source —Medication studyAges 18–65FranceAddiction
Understand this study
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- GièresSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: April 23, 2024
- Recruitment status
- Completed
- Enrollment listed in the registry
- 12
- Sponsor
- Kinnov Therapeutics
- Sponsor type
- Biotech company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- France
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06147622
- Official title
Show the full official title
A Phase 1, Open-label, Cross-over Study in Healthy Volunteers to Assess the Pharmacokinetic Profile of Prazosin and Cyproheptadine Following Single Dose Oral Administration of KT110 Tablet and Following Administration of Alpress and Periactin Marketed Tablets
Get this study by email
Recruitment & locations
CompletedGières
Questions about this study
Who is behind this study?
The study sponsor is Kinnov Therapeutics.
Did this study involve medication?
Yes. The study involved medication, including Prazosin + cyproheptadine and KT110.
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
